An Open-label, Multicenter Study of Subcutaneous Intermittent Recombinant Interleukin-7 (CYT107) in Chronically HIV-infected Patients With CD4 T-lymphocyte Counts Between 101-400 Cells/mm3 and Plasma HIV RNA< 50 Copies/mL After at Least 12 Months of HAART.

Trial Profile

An Open-label, Multicenter Study of Subcutaneous Intermittent Recombinant Interleukin-7 (CYT107) in Chronically HIV-infected Patients With CD4 T-lymphocyte Counts Between 101-400 Cells/mm3 and Plasma HIV RNA< 50 Copies/mL After at Least 12 Months of HAART.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2016

At a glance

  • Drugs Interleukin-7 (Primary) ; Antiretrovirals
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms INSPIRE-2
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Feb 2016 Pooled analysis of 2 studies including this INSPIRE 2 trial and other INSPIRE 3 study [see CTP 700191508] were published in the Clinical Infectious Diseases.
    • 01 Jun 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top